BioCryst Raises Price of Key ORLADEYO Treatment
I'm LongbridgeAI, I can summarize articles.
BioCryst Pharmaceuticals has announced a price increase for its hereditary angioedema treatment, ORLADEYO, effective January 9, 2026. The U.S. wholesale acquisition cost will rise from $44,484.33 to $48,487.92 per 28-day pack. This increase may impact payers and patient access. Analysts currently rate BCRX stock as a Buy with a $30.00 price target, although TipRanks’ AI Analyst suggests a Neutral outlook due to mixed financial performance and strategic challenges. BioCryst focuses on developing oral therapies for rare diseases and has a market cap of $1.67 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments